Study of AAVrh10-h.SGSH Gene Therapy in Patients With Mucopolysaccharidosis Type IIIA (MPS IIIA)



Status:Recruiting
Conditions:Other Indications, Metabolic
Therapuetic Areas:Pharmacology / Toxicology, Other
Healthy:No
Age Range:Any
Updated:3/13/2019
Start Date:December 17, 2018
End Date:January 2022
Contact:Lysogene trial inquiries
Email:patientadvocacy@lysogene.com
Phone:+33 (0) 1 41 43 03 90

Use our guide to learn which trials are right for you!

Open-label, Single-arm, Multi-center Study of Intracerebral Administration of Adeno-associated Viral (AAV) Serotype rh.10 Carrying Human N-sulfoglucosamine Sulfohydrolase (SGSH) cDNA for Treatment of Mucopolysaccharidosis Type IIIA

MPS IIIA is predominantly a central nervous system disease causing cognitive disability,
progressive loss of acquired skills, behavioral and sleep disturbance. LYS-SAF302 is a gene
therapy which is intended to deliver a functional copy of the SGSH gene to the brain. This is
a phase 2-3 study to assess the efficacy in improving or stabilizing the neurodevelopmental
state of MPS IIIA patients.

The study is interventional, single arm and multi-center. Evolution under treatment will be
compared to expected natural evolution based on natural history studies.

Inclusion Criteria:

- Documented MPS IIIA diagnosis based on genotyping confirming the SGSH gene mutations

- Cognitive DQ score on BSID-III: 50% and above

Exclusion Criteria:

- Homozygous for the S298P mutation or non-classical severe form of MPS IIIA, based on
investigator's judgement.

- Participation in another gene or cell therapy clinical trial.

- Past use of SGSH enzyme replacement therapy for a period exceeding 3 months. A washout
period of at least 2 months is required prior to screening.

- Current participation in a clinical trial of another investigational medicinal
product.

- History of bleeding disorder or current use of medications that, in the opinion of the
investigator, place them at risk of bleeding following surgery.

- Any condition that would contraindicate treatment with immunosuppressants such as
tacrolimus, mycophenolate mofetil or steroids.
We found this trial at
5
sites
Minneapolis, Minnesota 55455
(612) 625-5000
Principal Investigator: Chester Whitley, MD
Phone: 612-625-1594
Univ of Minnesota With a flagship campus in the heart of the Twin Cities, and...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Houston, Texas
Phone: 832-825-1717
?
mi
from
Houston, TX
Click here to add this to my saved trials
New York, New York 10021
Phone: 646-962-2672
?
mi
from
New York, NY
Click here to add this to my saved trials
Orange, California 92868
Principal Investigator: Raymond Wang, MD
?
mi
from
Orange, CA
Click here to add this to my saved trials
Paris, 75012
Principal Investigator: Bénédicte Heron, MD
?
mi
from
Paris,
Click here to add this to my saved trials